Summary
(Reuters) -AbbVie said on Wednesday its migraine drug met the main goal and was superior to a widely used generic treatment in a head-to head late-stage trial. The U.S. drugmaker has been expanding and banking on its neuroscience portfolio after its blockbuster arthritis drug Humira began facing competition from several less expensive biosimilar versions.
Source: Reuters on MSN.com
Exclusive AI-Powered News Insights (For Members only)
Disclaimer:This content is AI-generated from various trusted sources and is intended for informational purposes only. While we strive for accuracy, we encourage you to verify details independently. Use the contact button to share feedback on any inaccuracies—your input helps us improve!
